News

ACY-1215T is at present being investigated in human trials to treat multiple myeloma. Acetylon chief executive officer Walter Ogier said, "Given the widespread interest in the development of

The Sevikar, a fixed dose combination of olmesartan medoxomil and amlodipine besylate tablets, is likely to be included on the national lists of compensated drugs. The combination will

The patent covers a core element of Rosetta’s microRNA technology in the development of cancer therapeutics associated with p53-negative cancers. Rosetta Genomics president and chief executive officer Kenneth

Adimab also announced the achievement of technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech. Adimab CEO Tillman Gerngross said, "We are now expanding our

The filing of an investigational new drug application with the FDA for a monoclonal antibody that was optimized using Xencor’s XmAb antibody technology prompted the milestone payment. Xencor

Daclatasvir is an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor. In the Phase II open-label clinical trial (AI447-017), patients were divided into two

The single-blind, randomized trial is expected to enrol 72 obese patients, with a body mass index between 30 and 35kg/m². The primary objective of the placebo-controlled trial is

ALD518 is a monoclonal antibody to the pro-inflammatory cytokine IL-6, which is under Phase 2 development by Bristol-Myers Squibb for autoimmune diseases, and by Alder for cancer-related conditions.

Admet Predictor 6.0 now integrated with MedChem Designer offers graphical user interface improvements, expanded multidimensional graphics output and enhanced capabilities for exporting results. SLP Admet cheminformatics team leader